![](/assets/default_company_panoramic_image-25937d8eab89e89a7dc30165ae221f7d4020dd13520c1d30da88bbbea34367f7.png)
![](https://gust-production.s3.amazonaws.com/uploads/startup/logo_image/117143/logo.png)
InnaVirVax
InnaVirVax is developing at the clinical stage an innovating therapy for HIV infection that will act in synergy with antiretrovirals.
- Stage Product In Development
- Industry Biotechnology
- Location Évry, IDF, France
- Currency EUR
- Founded March 2008
- Employees 10
- Website innavirvax.fr
Company Summary
InnaVirVax, incorporated in 2008, is a French biopharmaceutical company. Its most advanced project is an innovative therapy for HIV infection that has completed a Phase I/IIa clinical trial and been found to be safe and well tolerated. This therapy would act in synergy with antiretrovirals, reducing the morbity and mortality of this disease. At peak sales, it is expected yearly worth is expected to be more than €1 billion.
Team
-
Joël CROUZETChief Executive Officer & Chairman of the Board
Joel Crouzet, PhD, co-founder of InnaVirVax, with 20 years of experience in R&D, was Director of Research at Neurotech and AP Cells, and Departmental Director at Rhône-Poulenc Rorer (Sanofi Aventis). He invented two patents that are now in industrial use. He gained experience in business development as General Manager at Inserm-Transfert, and has received awards from Rhône-Poulenc, the French Academy of Sciences and the French Senate.
-
Shahin GHARAKHANIANChief Medical Officer
Shahin Gharakhanian MD, DTM&H, Dip.PH specializes in HIV medicine and infectious diseases. Until recently, he was Vice-President of Vertex Pharmaceuticals Inc., Medicines Development Group, Global R&D. During his career, his jobs have ranged from the General Manager of a full-service Contract Research Organization to Program Executive leading product development, regulatory approval/launch, and has thus gain extensive expertise in these areas.
-
Nathalie BARANOperation Development Manager
Nathalie holds an MBA and has a PhD in endocrinology. She has gained experience if start-up development while working for several yeaNathalie Baran holds an MBA and a PhD in endocrinology. She gained experience of start-up development while working for several years at OSEO, the French Innovation Agency, and Genopole Entreprises, a Paris-region incubator. Her expertise lies in finance, grant raising and business development.
-
Raphael HO TSONG FANGClincial Operation Manager
Raphaël Ho Tsong Fang, DVM & PhD in microbiology and medical virology, has worked for eight years on SIV (Simian ImmunoDeficiency Virus) and HIV infections at the Pasteur Institute in Paris and at UCLA, Los Angeles where he gained considerable knowledge of HIV disease and pathogenesis. He also has expertise in the non-clinical assessment of vaccines. He has actively participated to the development of VAC-3S at InnaVirVax.
-
Dominique BATEJATHead of Pharmaceutical Development
Dominique Batéjat, Ms has expertise in biochemistry, molecular biology and pharmaceutical development. Her industrial experience includes working for Cellectis and Nautilus Biotech.
Advisors
-
Frédéric Lerner, SCP Lerner Friggeri & AssociésLawyerUnconfirmedIn ExtensoAccountantUnconfirmed
Previous Investors
-
Cap Decisif ManagementUnconfirmedG1J Ile-de-France, Fonds Régional de Co-Investissement, FaDièseUnconfirmedPradeyrol DéveloppementUnconfirmed
Starting a startup?
Join the world's largest startup network for guidance, tools, and fundraising opportunities.